%0 Journal Article
%T Automation on an Open
%A Benjamin Gille
%A Britta Brix
%A Cindy Francois
%A Erik Stoops
%A Hugo Vanderstichele
%A Jos Tournoy
%A Koen Poesen
%A Leentje Demeyer
%A Lieselot Dedeene
%A Maxim De Schaepdryver
%A Rik Vandenberghe
%A Stefanie Lefever
%J SLAS TECHNOLOGY: Translating Life Sciences Innovation
%@ 2472-6311
%D 2018
%R 10.1177/2472630317750378
%X The lack of (inter-)laboratory standardization has hampered the application of universal cutoff values for Alzheimer＊s disease (AD) cerebrospinal fluid (CSF) biomarkers and their transfer to general clinical practice. The automation of the AD biomarker immunoassays is suggested to generate more robust results than using manual testing. Open-access platforms will facilitate the integration of automation for novel biomarkers, allowing the introduction of the protein profiling concept. A feasibility study was performed on an automated open-access platform of the commercial immunoassays for the 42-amino-acid isoform of amyloid-汕 (A汕1每42), A汕1每40, and total tau in CSF. Automated A汕1每42, A汕1每40, and tau immunoassays were performed within predefined acceptance criteria for bias and imprecision. Similar accuracy was obtained for ready-to-use calibrators as for reconstituted lyophilized kit calibrators. When compared with the addition of a standard curve in each test run, the use of a master calibrator curve, determined before and applied to each batch analysis as the standard curve, yielded an acceptable overall bias of ˋ2.6% and ˋ0.9% for A汕1ˋ42 and A汕1每40, respectively, with an imprecision profile of 6.2% and 8.4%, respectively. Our findings show that transfer of commercial manual immunoassays to fully automated open-access platforms is feasible, as it performs according to universal acceptance criteria
%K Alzheimer＊s disease
%K cerebrospinal fluid
%K biomarkers
%K automation
%K open-access platform
%U https://journals.sagepub.com/doi/full/10.1177/2472630317750378